Driving Under the Influence, Public Policy, and Pharmacy Practice

  title={Driving Under the Influence, Public Policy, and Pharmacy Practice},
  author={Nicholas S Sigona and Karl G. Williams},
  journal={Journal of Pharmacy Practice},
  pages={119 - 123}
Motor vehicle accidents due to prescription drug impairment have increased in the past decade. Typically, impairment is associated with medications causing excessive drowsiness, such as opioids or benzodiazepines, but the scope of driving under the influence (DUI)-drug charges is reaching into medications that are not typically considered impairing, such as antipsychotics, antiepileptics, and mood stabilizers. Data associating medication use with driving impairment are growing, especially with… 
Professional Drivers’ Knowledge About the Influence of Medicines that May Impair Driving
Findings could help to identify drivers, who are at increased risk for using potentially impairing medicines, to inform and educate them, and to prevent driving under the influence of medicines.
Receipt of Warnings Regarding Potentially Impairing Prescription Medications and Associated Risk Perceptions in a National Sample of U.S. Drivers.
Evidence of missed opportunities for information provision on impaired driving is provided, subgroups that may warrant enhanced interventions are identified, and preliminary evidence that receipt of impairment warnings is associated with increased perceptions of driving-related risk is provided.
Different aspects of driving under the influence of benzodiazepines
Experimental and epidemiological studies suggest a negative influence of benzodiazepines on driving skills, a dose-dependent impairment and an increased accident risk that can be concluded due to the
Benzodiazepines and driving pharmacological and legal aspects
Both physicians and pharmacists should advise their patients of the impairing effects of benzodiazepines, particularly in relation to drowsiness and sedation, and the implication of these effects on driving skills.
Pharmacists’ perceptions and communication of risk for alertness impairing medications
Population-Based Registry Analysis of Antidiabetics Dispensations: Trend Use in Spain between 2015 and 2018 with Reference to Driving
The trend of antidiabetics use in Castilla y León from 2015 to 2018 is presented through a population-based registry study and it is necessary that the health authorities include information on DIMs, such as the DRUID classification, in the prescription and dispensing software.
Positive Experiences Among DUI Offenders in Court-Mandated Substance Abuse Treatment
Positive Experiences Among DUI Offenders in Court-Mandated Substance Abuse Treatment by Katarzyna Pilewicz MA, Adler University, 2009 BS, Polish Open University, 1999 Dissertation Submitted in


Hospital Outpatients’ Responses to Taking Medications With Driving Warnings
There was a very high level of confidence in this group that they could determine whether they were personally affected by the medication, which may be a problem from a safety perspective, and a review of the Australian warning system and wider dissemination of information on medication treatment effects would be useful.
The mirage of impairing drug concentration thresholds: a rationale for zero tolerance per se driving under the influence of drugs laws.
It is suggested that there has been a search for drug blood concentrations that are the equivalent of the 0.08 g/dL threshold for alcohol-impaired driving in the United States, and that such equivalents are a mirage, and cannot be determined due to variable drug tolerance, lack of consistent relationships between drugBlood concentrations and impairment, innumerable drug combinations and multiple other factors.
Drugs and Driving
The authors present a global overview on the issue of drugs and driving and discusses the basic tenets of these laws, the various types of DUID statutes, the reasons why many existing laws hinder the prosecution of drugged drivers and the rationale for developing per se legislation.
Association of road-traffic accidents with benzodiazepine use
Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers.
Analysis of data for the crash-involved drivers suggested that these findings were not due to confounding by alcohol use or driving frequency, and the relative risk of injurious crash involvement for current users of any psychoactive drug was 1.5.
The Impact of Chronic Pain Patients' Psychotropic Drug Knowledge and Warning Labels on the Decision Whether to Drive a Car or Not
The results of this survey indicate that drug warning labels applied by Dutch pharmacies do not significantly change attitudes towards driving a car in patients taking medicinal drugs with psychotropic side effects.
Prescription of Antiepileptics and the Risk of Road Traffic Crash
Patients with prescription of antiepileptic drugs should be cautioned about their potential risk of road traffic crash, however this risk is however more likely to be related to seizures than to the effect of anti-epileptic medicines.
Psychotropic drugs and risk of motor vehicle accidents: a population-based case-control study.
Subjects taking antidepressants, BZDs and Z-drugs, separately, should be particularly cautioned for their increasing risk of MVAs.
Drivers can poorly predict their own driving impairment: a comparison between measurements of subjective and objective driving quality
The analyses show that subjective assessments do not robustly relate to actual driving performance either in terms of judgments about alertness before the drive or ratings of performance after the drive.
Psychoactive Medications and Injurious Motor Vehicle Collisions Involving Older Drivers
Use of antidepressants and opioid analgesics by older drivers was associated with increased risk for injurious motor vehicle collisions and there was no evidence of a doserelated effect with either class of drug.